European Medical Solutions
XBRU:ALEMS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 5-Year Average (15.3), the stock would be worth €4.7 (4% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 15.9 | €4.9 |
0%
|
| 5-Year Average | 15.3 | €4.7 |
-4%
|
| Industry Average | 3.5 | €1.09 |
-78%
|
| Country Average | 13.8 | €4.25 |
-13%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| BE |
|
European Medical Solutions
XBRU:ALEMS
|
20.7m EUR | 15.9 | 17.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -192 227.3 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
354.5B USD | 19.6 | 84.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.5B USD | 14 | 24.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
164.9B USD | 15 | 19.4 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -565.5 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.9B USD | 22 | 28.1 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.9B USD | 14.8 | 17.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42B EUR | 41.9 | 38 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.1B AUD | 13.1 | 30.5 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -60.1 | -61.8 |
Market Distribution
| Min | 1.8 |
| 30th Percentile | 10 |
| Median | 13.8 |
| 70th Percentile | 19.8 |
| Max | 598.6 |
Other Multiples
European Medical Solutions
Glance View
European Medical Solutions is a clinical stage biopharmaceutical company, which engages in the research and development of immunotherapy treatments for environmental and food allergies. The company is headquartered in Brussels, Bruxelles-Capitale and currently employs 135 full-time employees. The company went IPO on 2016-05-11. The firm offers a complete range of medical imaging systems on the international market. The company specializes in the design and manufacture of imaging systems for digital and conventional radiology and bone densitometry. The company offers products such as: radiology equipment (mobile radiology units, floating panel tables, mobile C-arm for operating room, etc. ), ultrasound bone densitometers (for the reconstruction of bone microarchitecture), X-ray bone densitometers (for the measurement of bone density), etc.
